Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study.
Evren
E
Caglayan
Sarah
S
Axmann
Martin
M
Hellmich
Pia
P
Moinzadeh
Stephan
S
Rosenkranz
D004311:Double-Blind Method; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D005385:Fingers / Q000098:blood supply / Q000503:physiopathology; D006207:Half-Life; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D017078:Laser-Doppler Flowmetry / Q000379:methods; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D011928:Raynaud Disease / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D012039:Regional Blood Flow / Q000187:drug effects*; D013450:Sulfones / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D016896:Treatment Outcome; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000069058:Vardenafil Dihydrochloride
D007093:Imidazoles; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride